ACD-101 is systemically administered via intravenous injection and reaches tumour cells over the intact blood-brain-barrier due to the pharmacological properties of the molecule. Glioma cells actively take up and retain ACD-101, allowing for diagnosis (124I-ACD-101) and therapy (131I-ACD-101). The treatment of inaccessibly localized tumours (e.g basal parts of the brain), or unrecognized micrometastases which cannot be sufficiently treated by surgery or radiation therapy becomes possible.

The anti-tumour effect induced by 131I-ACD-101 endo-radiotherapy is different in extent and nature compared to external field radiation. While endo-radiotherapy is cytocidal for glioma cells, conventional radiation therapy is only cytostatic (i.e. inhibiting growth).


  • Actively transported over intact blood brain barrier
  • Preferentially taken up and retained by tumor cells
  • Cytotoxic for glioma cells, inducing necrosis and apoptosis
  • Multimodal mode of action, reducing risk of resistance development Synergistic with XRT & other therapies


  • Systemic instead of local approach, avoiding intracerebral procedures (as in brachytherapy, chemo-wafers)
  • Toxicity profile well characterised (thyroid 131I therapy well established)
In the following sub-sections we present selected results of our development:
First human results can be found in the chapters diagnosis and therapy.

Contact Therapeia

Therapeia GmbH & Co. KG
Veilchenweg 38
01326 Dresden

Tel: +49 (0)351 4188 00000
Fax: +49 (0)351 4188 00009


or just use our contact form




Programmierung: screenfox New Media - Kamenz

Hosting: FORMALITY Deutschland